Strong Results and Pipeline Momentum Power Amgen's (AMGN) 2025 Rally [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
Amgen Inc. (NASDAQ:AMGN) has outperformed the broader market this year, supported by strong financial results and steady clinical progress, even as investors keep an eye on upcoming patent expirations. The stock is up more than 27% since the start of 2025. In the third quarter, revenue rose 12% from a year earlier to $9.6 billion. Several of the company's key growth drivers delivered solid numbers. Repatha, a treatment for high cholesterol, generated $794 million in sales during the period, a 40% increase from the prior year. Tezspire, Amgen's asthma therapy, posted revenue of $377 million, also up 40% year over year. Growth may slow over the next few quarters as biosimilar competition for denosumab, a bone-health drug sold under the Prolia and Xgeva brands, begins to gain traction. That pressure is real, and it is already on investors' radar. Amgen Inc. (NASDAQ:AMGN) still has multiple ways to offset that impact. Several existing products continue to offer years of sales growth,
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Erythropoietin Stimulating Agents Market Size to Reach USD 16.81 Billion by 2033, Driven by Rising chronic kidney disease and Chemotherapy-Induced Anemia Cases – SNS Insider [Yahoo! Finance]Yahoo! Finance
- Amgen Inc. (AMGN): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at Royal Bank Of Canada from $330.00 to $335.00. They now have an "outperform" rating on the stock.MarketBeat
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $400.00 to $403.00. They now have a "buy" rating on the stock.MarketBeat
- Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss [CNBC]CNBC
AMGN
Earnings
- 11/4/25 - Beat
AMGN
Sec Filings
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- 11/13/25 - Form 4
- AMGN's page on the SEC website